Arovella Therapeutics Ltd
F:E4NA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Arovella Therapeutics Ltd
F:E4NA
|
AU |
Intrinsic Value
The intrinsic value of 
Arovella Therapeutics Ltd (E4NA) under the Base Case is 0.006 EUR per share.
Compared with the current market price of 0.028 EUR, the stock appears
Overvalued by 78% .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Arovella Therapeutics Does
Arovella Therapeutics is a biotechnology company that develops cancer cell therapies. Its work centers on engineered immune cells, especially invariant natural killer T, or iNKT, cells, which are designed to recognize and attack cancer cells more effectively than the body’s natural defenses. The company’s main job is to turn early-stage scientific research into drug candidates that can be tested in patients.
- Headquarters
- Australia AU
- IPO date
- Jan 24, 2002
Earnings Waterfall
Arovella Therapeutics Ltd
The intrinsic value for Arovella Therapeutics Ltd (E4NA) under the Base Case is 0.006 EUR.
Compared with the current market price of 0.028 EUR, the stock appears Overvalued by 78% .